8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Guidelines for the automated evaluation of Elispot assays.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The presented protocol for Elispot plate evaluation summarizes how to implement the recommendations developed following the establishment of a large-scale international Elispot plate-reading panel and subsequent multistep consensus-finding process. The panel involved >100 scientists from various immunological backgrounds. The protocol includes the description and justification of steps for setting reading parameters to obtain accurate, reliable and precise automated analysis results of Elispot plates. Further, necessary adjustments for out-of-specification situations are described and examples are provided. The plate analysis, including parameter adjustments, auditing of results and necessary annotations, should be achievable within a time range of 10-30 min per plate. Adoption of these guidelines should enable a further reduction in assay variability and an increase in the reliability and comparability of results obtained by Elispot. These guidelines conclude the ongoing harmonization efforts for the enzymatic Elispot assay.

          Related collections

          Author and article information

          Journal
          Nat Protoc
          Nature protocols
          1750-2799
          1750-2799
          Jul 2015
          : 10
          : 7
          Affiliations
          [1 ] ZellNet Consulting, Inc., Fort Lee, New Jersey, USA.
          [2 ] LBPrice Statistical Consulting Ltd., Karmiel, Israel.
          [3 ] BioNTech Diagnostics GmbH, Mainz, Germany.
          [4 ] Association for Cancer Immunotherapy (CIMT), Mainz, Germany.
          [5 ] Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
          [6 ] Department of ImmunoOncology, GlaxoSmith Kline, Collegeville, Pennsylvania, USA.
          Article
          nprot.2015.068
          10.1038/nprot.2015.068
          26110715
          3b3fcda5-dd62-4599-90c3-d0eb1632a929
          History

          Comments

          Comment on this article